Emergency license (EUA) in the treatment of antibodies against COVID-19, developed by Vir Biotechnology Inc. and GlaxoSmithKline for the treatment of mild to moderate Covid-19 in people over 12 years of age provided by the US Food and Drug Administration (FDA),
Sotrovimab antibody has not been approved for patients being treated for Covid-19 or in need of oxygen therapy, the FDA has announced.
THE European Medicines Agency (EMA), as noted by AMPE, last week supported the use of the drug for patients who are at risk of becoming seriously ill and do not need oxygen.
(file photo)
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
